// App-Quantinova.ai

6 : Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

Researchers

Presenter

  • Dung T. Le

Principal Investigators

  • Johanna C. Bendell

  • Emiliano Calvo

  • Joseph W. Kim

  • Paolo Antonio Ascierto

  • Padmanee Sharma

  • Patrick Alexander Ott

  • Petri Bono

  • Dirk Jaeger

  • T.R. Jeffry Evans

  • Filippo G. De Braud

  • Ian Chau

  • Olaf Christensen

  • Christopher Harbison

  • Chen-Sheng Lin

  • Yelena Yuriy Janjigian

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Yale University Medical Center / Yale Cancer Center, New Haven, CT

  • Istituto Nazionale Tumori IRCCS, Naples, Italy

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • The Royal Marsden Hospital, London, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Spain

  • Italy

  • Finland

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01928394

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved